We evaluate treatment methods for refractory psychiatric conditions, aiming to improve outcomes and clinical practice. The KetECT study, which compared ketamine with electroconvulsive therapy (ECT) in unipolar depression, has led to ketamine being considered an alternative for certain patients. Blood samples and cognitive data from KetECT will be analyzed to identify biomarkers that can predict treatment response and side effects. We have also studied ECT in pregnant women, where the treatment proved safe without significant effects on the fetus, and in children and adolescents, where the efficacy was comparable to that in adults. The SATIS study, which examined an accelerated form of repetitive transcranial magnetic stimulation in depression, demonstrated rapid treatment responses and provided insights into non-invasive brain stimulation. Future projects include psiAN, a study on psilocybin for anorexia nervosa, and KetECT Bipolar, comparing ketamine with ECT in bipolar depression.
